Aviado · Research
Longevity Daily
Friday, August 7, 2026
Listen
Today's Brief
Today's digest is anchored by a finding that should matter to anyone in their 40s or 50s: addressing just three cardiovascular risk factors during midlife could push back dementia onset by a full 13 years. Complementing that, new research shows SuperAger memory resilience owes more to modifiable habits than to lucky genes, while a Neuron study reveals tau protein directly hijacks mitochondria to drive Alzheimer's — and blocking that process reduces toxicity across species. In the supplement world, 2026 head-to-head trials edge the NMN vs. NR debate toward a resolution, and P&G's $3.8 billion Thorne acquisition signals that premium longevity supplements have fully crossed into the mainstream.
10 stories5 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
Three Midlife Cardiovascular Risk Factors Could Delay Dementia Onset by 13 Years
A new study finds that managing cardiovascular health risk factors during the critical midlife window — between ages 45 and 65 — could delay the onset of dementia by up to 13 full years. The research reframes dementia prevention as a midlife intervention problem, not a late-life inevitability, and identifies three specific cardiovascular health factors that drive cognitive decline risk when left unaddressed. This matters because it shifts the action window to decades before symptoms appear — when intervention is still highly effective. If your midlife cardiovascular health isn't actively managed, this is the study to bring to your next doctor's appointment.
Read more →Scientists Thought SuperAgers Had Lucky Genes — A Major Study Says Otherwise
A major new study challenges the assumption that people who retain youthful memory into their 80s and 90s simply won a genetic lottery. Researchers found the secrets behind SuperAger memory resilience to be more modifiable and more intriguing than previously thought — shifting the question from 'were you born lucky?' to 'what are you doing differently?' The findings point toward specific lifestyle and biological factors driving exceptional memory longevity, offering real targets for the rest of us.
Read more →Tau Hijacks Mitochondria to Drive Alzheimer's — And Blocking It Works Across Species
Research published in Neuron reveals that hyperphosphorylated tau — the protein forming toxic tangles in Alzheimer's brains — directly invades mitochondria and triggers a damaging energy reaction called reverse electron transport (RET), flooding neurons with destructive reactive oxygen species. This creates a self-amplifying loop: damaged mitochondria drive more tau phosphorylation, which damages more mitochondria. Crucially, blocking RET reduced tau toxicity in flies, mice, and human stem cell-derived neurons, establishing a previously unrecognized therapeutic target for Alzheimer's and other tauopathies.
Read more →Depression Shrinks a Key Memory Region in Older Brains — Independently of Alzheimer's
A new study finds that depression in older adults is specifically linked to volume loss in the CA23DG subfield of the hippocampus — a region central to memory formation and consolidation. Critically, this effect was independent of Alzheimer's biomarkers, meaning depression causes its own distinct, measurable form of structural brain damage. For older adults experiencing depression, the takeaway is urgent: untreated depression isn't just a mood disorder — it may be accelerating brain aging in ways that compound dementia risk.
Read more →Supplements & Compounds
'Exceeded Our Expectations': One Antioxidant Shows Promise for Keeping Aging Muscles Strong
Scientists report that a compound called LASSS — a targeted antioxidant — significantly boosts levels of hepatocyte growth factor (HGF), a protein critical for muscle repair and regeneration that declines sharply with age. Researchers expressed high confidence that the HGF-boosting effects will apply broadly across humans and animals, positioning LASSS as a potential tool for combating sarcopenia and supporting injury recovery. Caveat: the study appears preclinical; human trial data will be needed before any dosing recommendations can be made.
Read more →NMN vs. NR in 2026: Head-to-Head Trials Lean Toward NR as the More Efficient NAD+ Booster
A review of current human research — including 2026 head-to-head trials — suggests NR (nicotinamide riboside) is the more efficient oral precursor for raising blood NAD+ levels compared to NMN. NMN retains a growing evidence base and remains a legitimate option, but for those optimizing purely for NAD+ elevation, current data edges toward NR. The larger open question remains whether raising NAD+ in blood translates to meaningful longevity outcomes in humans — a debate no precursor comparison can yet settle.
Read more →Research & Papers
New 'Pasta' Transcriptomic Clock Can Tell Whether Longevity Interventions Are Actually Working
Researchers have developed Pasta, a transcriptomic clock that reads gene expression patterns to predict biological age — with one key advantage over existing clocks: it can accurately measure how specific compounds, interventions, and genetic modifications shift aging trajectories at the cellular level. Unlike epigenetic clocks based on DNA methylation, this RNA-based tool offers a new lens for evaluating which longevity drugs and protocols are genuinely moving the needle. Better measurement tools are one of the field's most pressing needs.
Read more →Aviado Research: Featured Analysis
Aviado Research's latest deep-dive brings its evidence-first approach to a key topic in longevity science, synthesizing current research into a clear, actionable perspective. Read the full analysis for sourced insights you can act on.
Read the full Aviado analysis →Lifestyle & Nutrition
Bryan Johnson's Optimization Culture May Be Undermining the One Thing That Actually Extends Life
Australia's ABC Religion & Ethics makes a pointed case: while longevity science deserves celebration, the rigid optimization lifestyle championed by Bryan Johnson — which this week became more complicated after he revealed a diagnosis of incurable autoimmune gastritis — is incompatible with the social connection that decades of research identify as one of the strongest predictors of long life. The irony runs deep: loneliness kills faster than most risk factors Johnson is optimizing against. Scientific self-improvement and human community need not be at odds, but the extremes of biohacking culture increasingly treat them as if they are.
Read more →Industry & Policy
P&G Acquires Thorne for $3.8 Billion — The Mainstreaming of Premium Longevity Supplements Is Complete
Procter & Gamble is acquiring Thorne Health, one of the most trusted clinical-grade supplement brands in the longevity space, from LVMH-backed L Catterton in a $3.8 billion deal expected to close in Q4 2026. When one of the world's largest consumer goods companies pays nearly $4 billion for a supplement brand, the category's legitimacy is difficult to dispute. Thorne loyalists should watch closely for potential changes to product formulation philosophy and quality standards as the brand integrates into a mass-market parent company.
Read more →